This study is looking at a new combination of cancer drugs for primary central nervous system lymphoma (called CNS lymphoma for short). It is a cancer of the lymphatic system that starts in the brain or spinal cord.
Doctors often treat CNS lymphoma with chemotherapy. Sometimes the lymphoma does not respond to chemotherapy or it comes back after treatment. In this situation there is no standard treatment.
In this trial are looking at giving a new combination of the following cancer drugs
- Thiotepa
- Ifosphamide
- Etoposide
- Rituximab
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
| Chief Investigator: |
Dr Christopher Fox |
| Sponsor: |
University of Birmingham |
| Funders: |
Bloodwise |
| Disease Site: |
Primary Central Nervous System Lymphoma |
| Trial Type: |
Phase I/II |
| Status: |
Open |
| UKCRN Study ID: (if applicable) |
17668 |
| Open to new sites? |
Yes |
| Recruitment start date: |
Feb 2015 |
| Anticipated Recruitment end date |
Feb 2018 |
| CRCTU Trial Management Team: |
Haematology Team |
| Trial E-mail Address: |
TIER@trials.bham.ac.uk |